Type1 Diabetes Clinical Trial
Official title:
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study
The purpose of this extension study is to continue to follow the participants who completed the CLVer RCT for up to 3 additional years. The goal for Cohort A is to evaluate the longer-term effects of verapamil on preservation of β-cell function as measured by C-peptide levels obtained during a mixed meal tolerance test (MMTT). For both Cohorts A and B, the goal is to determine if the high degree of glycemic control achieved during CLVer with HCL can be maintained once the intensive engagement of the study team is discontinued. At the completion of the RCT, study treatments end. Thus, during the extension study, diabetes management is performed as part of usual care and there is no study treatment.
Participants who complete the CLVer RCT will be eligible to enroll in the CLVer Extension Study. Informed consent and assent, when applicable, will be obtained. Participants will be contacted every 3 months at which time continuous glucose monitoring (CGM) data will be obtained if a CGM device is being used and medical history (including recent point-of-care or local laboratory HbA1c values) will be reviewed; a usual care visit performed by study staff may be considered a study contact. A study visit will occur yearly to update the diabetes and medical history, measure height and weight, determine Tanner staging, download CGM data if available, perform an MMTT, and obtain blood samples for central lab measurement of HbA1c and plasma for storage if consented. Other than the central lab samples, there are no study-specific procedures or data collection that would not be performed as part of standard care. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05536232 -
Residual Insulin Secretion in Patients With Type 1 Diabetes Under a Low Carbohydrate Diet or a Ketogenic Diet
|
N/A | |
| Completed |
NCT04255381 -
Yale-Harvard Hotel-based Closed-Loop Studies in Children (HY-GRAID)
|
N/A | |
| Completed |
NCT04625595 -
Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes
|
Phase 1 | |
| Completed |
NCT04002557 -
Optimising Consultation Summaries to Promote Good Health
|
||
| Completed |
NCT05876273 -
Neural-net Artificial Pancreas (NAP)
|
N/A | |
| Withdrawn |
NCT03236558 -
The Role of the Thymus in Type I Diabetes.
|
N/A | |
| Completed |
NCT03179280 -
Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia
|
N/A | |
| Recruiting |
NCT06253351 -
Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age With Type 1 Diabetes
|
||
| Completed |
NCT01357603 -
Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM
|
Phase 1 | |
| Completed |
NCT04233034 -
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes
|
Phase 3 | |
| Active, not recruiting |
NCT03782636 -
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
|
Phase 2 | |
| Completed |
NCT04520971 -
Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes
|
N/A | |
| Recruiting |
NCT05766657 -
Evaluation of an Anti-inflammatory Diet in Autoimmune and Metabolic Diseases
|
N/A | |
| Completed |
NCT01838083 -
Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus
|
Phase 1 |